+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Eviplera"

Eviplera - API Insight, 2022 - Product Thumbnail Image

Eviplera - API Insight, 2022

  • Drug Pipelines
  • January 2022
  • 30 Pages
  • Global
From
Eviplera- Drug Insight, 2019 - Product Thumbnail Image

Eviplera- Drug Insight, 2019

  • Report
  • January 2019
  • 35 Pages
  • Global
From
  • 3 Results (Page 1 of 1)
Loading Indicator

Eviplera is a combination antiretroviral drug used to treat HIV infection. It is a fixed-dose combination of three drugs: emtricitabine, rilpivirine, and tenofovir disoproxil fumarate. It is used to treat HIV-1 infection in adults and adolescents aged 12 years and older. The drug works by blocking the action of the HIV virus, preventing it from replicating and spreading in the body. It is taken once daily, with or without food. Eviplera is part of a larger market of infectious diseases drugs, which are used to treat a variety of illnesses caused by bacteria, viruses, fungi, and parasites. These drugs are used to treat a range of conditions, from common colds to more serious illnesses such as HIV, malaria, and tuberculosis. Some companies in the Eviplera market include Gilead Sciences, Janssen Pharmaceuticals, and ViiV Healthcare. Show Less Read more